Gilead Sciences announced it will acquire Ouro Medicines for $1.675 billion upfront, marking the pharma giant's entry into the T cell engager therapeutic space. The deal focuses on Ouro's autoimmune program and involves an unusual arrangement that may include participation from Galapagos.
The acquisition represents Gilead's strategic push into autoimmune therapeutics, an area where T cell engagers are emerging as a promising new class of treatments. T cell engagers work by redirecting the body's immune system to target specific disease-causing cells, offering potential advantages over traditional autoimmune therapies.